These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 1607247)

  • 1. Liposome suppression of proliferative vitreoretinopathy.
    Maurice D
    Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2344. PubMed ID: 1607247
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes.
    Assil KK; Hartzer M; Weinreb RN; Nehorayan M; Ward T; Blumenkranz M
    Invest Ophthalmol Vis Sci; 1991 Oct; 32(11):2891-7. PubMed ID: 1917392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.
    Joondeph BC; Peyman GA; Khoobehi B; Yue BY
    Ophthalmic Surg; 1988 Apr; 19(4):252-6. PubMed ID: 3362494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.
    Wiedemann P; Sorgente N; Bekhor C; Patterson R; Tran T; Ryan SJ
    Invest Ophthalmol Vis Sci; 1985 May; 26(5):719-25. PubMed ID: 3997421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of growth stimulating activity of the vitreous during PVR.
    Yang CM; Cousins SW
    Invest Ophthalmol Vis Sci; 1992 Jul; 33(8):2436-42. PubMed ID: 1634341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes.
    Barza M; Stuart M; Szoka F
    Invest Ophthalmol Vis Sci; 1987 May; 28(5):893-900. PubMed ID: 3106257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of liposomes as intravitreal drug delivery system].
    Bejjani RA; Jeanny JC; Bochot A; Behar-Cohen F
    J Fr Ophtalmol; 2003 Nov; 26(9):981-5. PubMed ID: 14631286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin receptor expression by retinal pigment epithelial cells in proliferative vitreoretinopathy.
    Baudouin C; Brignole F; Gastaud P
    Arch Ophthalmol; 1991 Sep; 109(9):1195-6. PubMed ID: 1929946
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy].
    Bi HS; Cui Y; Zhang JH; Wang XR; Xie XF
    Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):37-41. PubMed ID: 16638279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and retinal toxicity of intravitreal liposome-encapsulated 5-fluorouridine.
    García-Arumí J; Pascual R; Fonseca MJ; Isart FR; Casaroli R; Mateo C; Corcostegui B
    Ophthalmologica; 1997; 211(6):344-50. PubMed ID: 9380351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trace elements iron, copper and zinc in vitreous of patients with various vitreoretinal diseases.
    Pai HV
    Indian J Ophthalmol; 2004 Dec; 52(4):348; author reply 348-9. PubMed ID: 15693342
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of drug treatments for proliferative vitreoretinopathy using vitreous microtensiometry.
    Moorhead LC; Sepahban S; Armeniades CD
    Ann Ophthalmol; 1991 Sep; 23(9):349-55. PubMed ID: 1741609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy.
    Hagedorn M; Esser P; Wiedemann P; Heimann K
    Ger J Ophthalmol; 1993 Feb; 2(1):28-31. PubMed ID: 7679595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative and anticontractile effects of liposome encapsulated fluoroorotate.
    Heath TD; Lopez NG; Lewis GP; Stern WH
    Invest Ophthalmol Vis Sci; 1987 Aug; 28(8):1365-72. PubMed ID: 3610553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearance and localization of intravitreal liposomes in the aphakic vitrectomized eye.
    Stern WH; Heath TD; Lewis GP; Guerin CJ; Erickson PA; Lopez NG; Hong KL
    Invest Ophthalmol Vis Sci; 1987 May; 28(5):907-11. PubMed ID: 3032840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermia and temperature-sensitive liposomes: selective delivery of drugs into the eye.
    Khoobehi B; Peyman GA; Niesman MR; Oncel M
    Jpn J Ophthalmol; 1989; 33(4):405-12. PubMed ID: 2625775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trace elements iron, copper and zinc in vitreous of patients with various vitreoretinal diseases.
    Konerirajapuram NS; Coral K; Punitham R; Sharma T; Kasinathan N; Sivaramakrishnan R
    Indian J Ophthalmol; 2004 Jun; 52(2):145-8. PubMed ID: 15283220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine.
    Peyman GA; Schulman JA; Khoobehi B; Alkan HM; Tawakol ME; Mani H
    Retina; 1989; 9(3):232-6. PubMed ID: 2512600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of acidic fibroblast growth factor in proliferative vitreoretinopathy membranes.
    Malecaze F; Mathis A; Arné JL; Raulais D; Courtois Y; Hicks D
    Curr Eye Res; 1991 Aug; 10(8):719-29. PubMed ID: 1717200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.
    Shinohara K; Tanaka M; Sakuma T; Kobayashi Y
    Ophthalmic Surg Lasers Imaging; 2003; 34(4):299-305. PubMed ID: 12875458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.